NICE is recommending that women diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) receive regular monitoring through annual health reviews. The guidance focuses on the “common but overlooked” nature of the condition and aims to ensure that clinicians review symptoms and assess the effectiveness of current treatment. Under the recommendation, health professionals are expected to see patients each year so care can be adjusted if symptoms change or if treatments need refinement. The reviews are intended to support ongoing management of PMOS rather than treat it as a one-time diagnosis. The reporting highlights that the aim is to improve recognition and consistent follow-up for a large patient population. Overall, the guidance sets an expectation for yearly assessment by health services to help track the condition over time and maintain appropriate treatment, according to NICE.